ArticleAmerican journal of translational research2021
miR-506-3p can inhibit cell proliferation and is a diagnostic and prognostic marker of liver cancer.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 citations in OpenAlex.
- circ-FSCN1 affects ferroptosis and cell viability in NSCLC via the miR-506-3p/SLC7A1 pathway.Translational oncology · 2026Article
- SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway.Cancer biology & medicine · 2026Article
- Non-coding RNAs and Hippo signaling in non-small cell lung cancer: emerging roles as biomarkers and therapeutic targets.Discover oncology · 2025Review
- Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- The protective effect and antitumor activity ofFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt the time of diagnosis, most patients with liver cancer (LC) are at advanced stage, which increases the difficulty of treatment. MiR-506-3p is considered an anti-oncogene in a wide spectrum of malignancies. This investigation aims to determine the clinical implications of miR-506-3p in diagnosis and prognosis of LC.
methodsThe expression of miR-506-3p in tissues and serum samples of 92 LC patients was detected using quantitative real-time PCR (qRT-PCR), and the connection between serum miR-506-3p and pathologic features of LC patients was analyzed. The diagnostic efficacy of miR-506-3p in LC was visualized by Receiver Operating Characteristic (ROC) curves, its prognostic implications in LC were confirmed by follow-up, and its impact on LC cell proliferation was analyzed by CCK-8 assay.
resultsmiR-506-3p was lowly expressed in LC tissues and serum samples. Reduced serum miR-506-3p expression indicated larger tumor size, higher TNM stage, and poorer differentiation degree in LC patients. The area under the curve (AUC) of serum miR-506-3p in diagnosing LC was 0.911, and for distinguishing tumor size, TNM stage and pathologic differentiation degree, AUC was 0.751, 0.825 and 0.777, respectively. Kaplan-Meier analysis demonstrated decreased overall survival in patients presenting with reduced serum miR-506-3p. Cox proportional hazards regression model analysis revealed that TNM staging and low serum miR-506-3p expression were independent prognostic factors in patients with LC.
conclusionmiR-506-3p, capable of inhibiting LC cell proliferation, is a possible diagnostic and prognostic biomarker of LC.
Indexed as
Identifiers
34786079PMC8581929W3211462088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.